Revvity’s Euroimmun division has launched the IDS i20, a new fully automated platform which streamlines chemiluminescence immunoassays (ChLIA) for laboratories.
The IDS i20 carries both CE marking and US Food and Drug Administration (FDA) listing. It is said to enhance laboratory operations by integrating multiple speciality assays on a single device, thereby offering increased reagent capacity and higher test throughput.
The system supports the simultaneous processing of 20 analytes across six diagnostic specialties, including endocrinology, allergy, autoimmune and infectious diseases, Alzheimer’s disease, and therapeutic drug monitoring.
Unlike traditional manual or semi-automated processes, the IDS i20 offers laboratories an automated solution for ChLIA processing, improving flexibility and efficiency.
Euroimmun chief technical officer Bianca Huth said: “With the IDS i20 instrument, we’re able to support our customers making the transition from manual and semi-automated processing to a fully automated solution for enhanced immunodiagnostics workflows.
“Having been built on decades of experience in laboratory automation, the IDS i20 platform is intended to meet or exceed laboratories’ demands for reliability, versatility and usability.”
Capable of handling up to 140 tests per hour, the IDS i20 is the latest model in the IDS i-device series.
The platform incorporates advanced software for adaptability and scalability, featuring a user-friendly interface that adheres to current ergonomic, usability, and cybersecurity standards.
Continuous loading capabilities and integrated cooling of reagent cartridges support uninterrupted system operation, optimising efficiency and reducing manual intervention.
Last month, Revvity announced its financial results for the first quarter ending 30 March 2025. The company’s GAAP earnings per share was $0.35, an increase from $0.21 in the same quarter of the previous year.
Revenue for the reported quarter reached $665m, up from $650m year-over-year.
